104675-29-8

Basic information

• Product Name: Velnacrine
• Synonyms: Velnacrine;1,2,3,4-Tetrahydro-9-aminoacridin-1-ol maleate;1,2,3,4-Tetrahydro-9-aminoacridine-1-ol;9-Athco;C056424
• CAS NO: 104675-29-8
• Molecular Formula: C13H14N2O
• Molecular Weight: 214.267
• Mol File: 104675-29-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 245°
• Boiling Point: 450.3 °C at 760 mmHg
• Flash Point: 226.1 °C
• Appearance: /
• Density: 1.315 g/cm³
• Vapor Pressure: 6.77E-09mmHg at 25°C
• Refractive Index: 1.726
• CAS DataBase Reference: Velnacrine(CAS DataBase Reference)
• NIST Chemistry Reference: Velnacrine(104675-29-8)
• EPA Substance Registry System: Velnacrine(104675-29-8)

Safety Data

• Hazardous Substances Data: 104675-29-8(Hazardous Substances Data)

Usage

Uses

Inhibitor (cholinesterase).

Brand name

Mentane (Hoechst-Roussel).

InChI:InChI=1/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)

Upstream product

• 104675-26-5 9-Amino-1,2,3,4-tetrahydroacridin-1-one 
• 1684-40-8 tacrine monohydrochloride 
• 504-02-9 1,3-cylohexanedione 
• 104675-23-2 N-(3-oxocyclohexen-1-yl)-2-aminobenzonitrile 
• 1885-29-6 anthranilic acid nitrile 
• 67-63-0 isopropyl alcohol 

Related news

Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of Velnacrine (cas 104675-29-8) maleate08/20/2019

Velnacrine maleate (Mentane®) is an aminoacridine drug developed for the treatment of Alzheimer's disease. Although velnacrine maleate has not been observed to cause prominent cytotoxicity in in vitro hepatocyte cultures, this drug was associated with elevated serum levels of hepatic enzyme...detailed

Double-blind placebo-controlled study of Velnacrine (cas 104675-29-8) in Alzheimer's disease08/19/2019

The present study assessed the safety and efficacy of the cholinesterase inhibitor, velnacrine, for treating the cognitive symptoms of Alzheimer's disease. Patients (N = 236) meeting NINCDS-ADRDA criteria for Alzheimer's disease entered a double-blind, placebo-controlled dose-ranging p...detailed

Spectrofluorimetric determination of Velnacrine (cas 104675-29-8) in human serum and urine08/18/2019

A simple, sensitive and rapid spectrofluorimetric method to determine velnacrine, a cholinesterase inhibitor, has been developed and validated. The influence of pH, temperature, ionic strength, presence of excipients, metal ions and surfactants on the fluorescence intensity has been studied. The...detailed

Relevant articles and documents

Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: In vitro/in vivo comparisons

1. Incubations of tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate, THA) with a primary suspension of rat hepatocytes for 2 min resulted in formation of the 1-hydroxy derivative as the major metabolite with smaller amounts of the 2- and 4-hydroxy metabolites. 2. Apparent V(max) and K(m) for THA metabolism were 12.4 ± 3.3 nmol/min/g liver and 0.98 ± 0.34 μM respectively. 3. Incubations of THA for longer time-periods (> 10 min) resulted in irreversible binding of THA-derived radioactivity to hepatocellular protein. The apparent maximal rate of irreversible binding (B(max)) was 76.7 ± 30.5 pmol equivalents bound/h/mg cell protein, whereas the apparent K(b) for binding was 2.8 ± 1.4 μM. 4. The kinetic parameters, V(max) and K(m), were used to predict steady-state extraction ratios (ER(SS)) for various THA input concentrations (C(in)) in single-pass perfused rat liver. At low input concentrations (0.72-0.85 μM; C(in) K(m)), ER(SS) of THA was approximately 1. For higher C(in) (14.05, 20.72, 20.88 μM; C(in) ≥ K(m)), the calculated ER(SS) was markedly decreased with 0.300, 0.296 and 0.261, respectively. 5. The intrinsic clearance of THA (Cl(i)) estimated from in vitro hepatocyte data was 6.7 ml/min/g liver while the apparent oral THA clearance (Cl(oral)) calculated from in vivo rat data was 6.6 ml/min/g liver.

Use of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds for the treatment of aids

There is disclosed the use of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds of the formula below, where Xis hydrogen, loweralkyl or halogen; and Ris hydrogen, loweralkyl or benzyl; for the treatment of acquired immune deficiency syndrome (AIDS).

9-Amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments

-